...Los Angeles, University of Manchester ; Boston Children’s Hospital Corporate partners: Oxford Biomedica plc , PharmaCell B.V....

..."eats doses," he said. However, Nasser Sadr, manager of process development and research at CMO PharmaCell B.V....
...Bethesda, Md. New WuXi Life Science Ltd., Shanghai, China Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland PharmaCell B.V....

...TiGenix's cGMP cell therapy production facility for €5.8 million ($7.8 million) (see BioCentury, Feb. 3). PharmaCell B.V....

...PharmaCell will purchase TiGenix's cGMP cell therapy production €5.8 million ($7.9 million). PharmaCell will also acquire...
...$4.8 million) up front and a final payment of €750,000 ($1 million) after three years. PharmaCell...
...€2.3 million ($3 million) in ChrondoCelect sales for the six months ended June 30, 2013. PharmaCell B.V....

...The companies declined to disclose details (see BioCentury, Sept. 23). Dendreon Corp. (NASDAQ:DNDN), Seattle, Wash. PharmaCell B.V....

...and produce the cell line and Alloksys will conduct preclinical and clinical testing. Cevec and PharmaCell...
...IP. Alloksys Life Sciences B.V. , Bunnik, the Netherlands Cevec Pharmaceuticals GmbH , Cologne, Germany PharmaCell B.V....

...Euronext:PHI; PHG, Eindhoven, the Netherlands). Biotech companies Pharming Group N.V. (Euronext:PHARM, Leiden, the Netherlands) and Pharmacell B.V....

...CYN purchased a 20% stake in PharmaCell for an undisclosed amount of cash. In exchange, CYN...
...for an undisclosed amount of cash. In exchange, CYN said it will have access to PharmaCell's...
...manufacture cell therapy products. CYN, which has an option to acquire the remaining 80% of PharmaCell...